ArticleEndocrine2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RET p.Cys634-driven progression of hereditary vs. sporadic medullary thyroid cancer.Endocrine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis research, drawing on genealogical information gleaned over 40 years, aimed to clarify to what extent RET germline mutations causing multiple endocrine neoplasia 2A have been inherited.
methodsGeospatial inheritance of 30 different RET germline mutations was explored by mapping gene carriers to the postal code area of residence and year of birth of the earliest affected common ancestor.
resultsThe geospatial analyses revealed 13 single-family clusters among 30 different RET mutations, which involved 3 of 8 high-risk mutations and 10 of 16 intermediate-risk mutations but none of the 6 low-risk mutations. Of these 30 RET mutations, at least 15 RET mutations had been transmitted to offspring for more than 100 years. The oldest familial RET mutations dated back to the second half of the 19th century: to at least 1876 (p.Cys611Phe/c.1832G>T), 1880 (p.Cys634Arg/c.1900T>C), 1895 (p.Cys634Phe/c.1901G>T), 1897 (p.Ser891Ala/c.2671T>G), and 1899 (p.Cys618Phe/c.1853G>T). Another set of 10 RET mutations extended to the early 20th century: to at least 1902 (p.Glu768Asp/c.2304G>C), 1903 (p.Cys634Tyr/c.1901G>A), 1904 (p.Leu790Phe/c.2370G>T), 1905 (p.Cys618Ser/c.1852T>A), 1908 (p.Val804Met/c.2410G>A), 1910 (p.Cys611Phe/c.1832_1833delinsTT), 1914 (p.Cys609Gly/c.1825T>G, p.Cys634Gly/c.1900T>G, and p.Leu790Phe/c.2370G>C), and 1919 (p.Cys620Phe/c.1859G>T). The remaining 15 RET mutations could be traced back no farther than to between 1924 (p.Cys611Tyr/c.1853G>A) and 1966 (p.Cys618Arg (c.1852T>C) but exhibited geographical patterns suggestive of, or consistent with, consecutive migration outside of the area of familial origin.
conclusionThe longstanding transmission of the MEN2A trait across multiple generations, often over centuries, requires meticulous identification of all RET mutation carriers who stand to gain tremendously from earlier, hence more limited, surgical interventions.
Indexed as
Identifiers
40715712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.